News Patients may have quit statins after media row Coverage may have given "disproportional weight" to concerns over side effects.
News IDEAYA/Servier PKC drug aces uveal melanoma trial Servier $210m bet on IDEAYA's uveal melanoma therapy darovasertib seems to have paid off, as a trial sets up regulatory filings later in 2026.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
